Lv0
0 积分 2022-11-16 加入
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
2天前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
2天前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
8天前
已完结
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
8天前
已完结
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
9天前
已完结
Epidemiological trend of cervical cancer
21天前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
3个月前
已完结
Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer
3个月前
已完结
放射性碘难治性分化型甲状腺癌诊治管理指南(2024版)
3个月前
已完结
BRAF mutations in thyroid cancer
3个月前
已完结
皖公网安备34019202002308
